Navigation Links
FDA clears test developed in partnership with VCU researcher
Date:5/22/2012

RICHMOND, Va. (May 22, 2012) The Food and Drug Administration has approved a new test to help physicians diagnose a group of rare cell disorders. The test, or assay, was developed by an expert at Virginia Commonwealth University in the field of mast cells.

Lawrence Schwartz, M.D., Ph.D., chair of the Division of Rheumatology, Allergy and Immunology and the Charles and Evelyn Thomas Professor of Medicine at VCU, has spent more than 30 years researching mast cells. These cells are vital to the inflammatory process within the body and may play protective roles in wound healing and fighting infections.

"When a mast cell is triggered, it releases several strong chemicals into the body, including histamine and tryptase. Histamine causes itching, swelling, wheezing and sneezing and other signs and symptoms of allergic reactions," said Schwartz.

Mastocytosis, a group of rare chronic disorders found in both children and adults, is caused by the presence of too many of these mast cells in the body. If there are too many mast cells, the increased burden of chemicals released from these cells can cause several symptoms that range in intensity from mild to severe.

Because mast cells play a role in allergic reactions, the symptoms of mastocytosis are often similar to an allergic reaction. However, mastocytosis may occur spontaneously rather than be triggered by an allergen.

The FDA has cleared ImmunoCAP Tryptase, a new diagnostic assay, to measure the level of tryptase in the blood as an aid in the diagnosis of systematic mastocytosis. A persistently elevated baseline level of tryptase is an indication of possible mastocytosis.

"A physician cannot diagnose systematic mastocytosis based only on a physical examination. The FDA approval of the tryptase assay will provide doctors with an additional diagnostic tool," said Schwartz.

VCU first licensed the assay in 1993 to Pharmacia, now named Thermo Fisher Scientific Inc. The assay has one FDA-approved application helping to diagnose mastocytosis and several potential applications, including the diagnosis of systemic anaphylaxis, the prediction of increased risk for future episodes of severe anaphylaxis and use by medical examiners to evaluate cause of death.

"When somebody dies without a clear cause, by measuring postmortem tryptase levels, an increased level of tryptase provides support for an anaphylactic event near the time of death," said Schwartz.


'/>"/>
Contact: Frances Dumenci
fdumenci@vcu.edu
804-828-7701
Virginia Commonwealth University
Source:Eurekalert

Related medicine news :

1. FDA clears new IMMY and University of Nevada, Reno life-saving blood test
2. FDA clears biomarker test for ovarian cancer
3. Researchers find process that clears cholesterol and could reverse major cause of heart attack
4. Flightless mosquitoes developed to help control dengue fever
5. New tool developed to help guide pancreatic cyst treatment
6. Innovative Technology Developed at AGH Accurately Monitors Healthcare Professionals' Handwashing Practices, Study Shows
7. Innovative Motorized and Mobile Medical Procedure Table Developed By MTI, Inc.
8. New scanning technology developed in £7M research center
9. Sickle cell treatment developed at LA BioMed enters Phase 3 clinical trial
10. Human clinical trial of NIH-developed dengue vaccine begins
11. New diabetes risk assessment developed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2020)... , ... May 26, 2020 ... ... previously unknown mechanism through which certain infections can impact the brain causing ... Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections) and PANS (Pediatric Acute-onset Neuropsychiatric ...
(Date:5/26/2020)... ... May 26, 2020 , ... Sex educator, activist, humanitarian, ... advocate Joan Price have just received the 2020 AASECT Audio Visual Award for jessica ... was the first of its kind to feature non-actors in its demonstrations and narratives ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... CRC’s Guide to Coordinating Clinical Research, CenterWatch eLearning , https://www.centerwatch.com/products/category/2764-elearning/product/472-the-crc-trainer ... CRC Trainer: An Interactive Companion to the CRC’s Guide to Coordinating Clinical ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... industry leader in cancer biomarker assays, announced today that Cigna has added ROMA® ... is a global health service company dedicated to improving the health, well-being, and ...
(Date:5/21/2020)... ... May 21, 2020 , ... Friends of Lisa Campbell, announce that Lisa Campbell, ... Planned Parenthood Southeast Advocates (PPSEA). PPSEA educates and lobbies on behalf of ... range of reproductive health care. PPSEA educates and lobbies on behalf of women’s health ...
Breaking Medicine News(10 mins):
(Date:5/27/2020)... (PRWEB) , ... May 27, 2020 , ... Hemp Health One’s Giving Away Free CBD ... products for the next 60 days. The company is hosting the daily giveaway contest on ... by following Hemp Health One’s Instagram page or Hemp Health One’s Facebook page. Then, like ...
(Date:5/26/2020)... ... May 26, 2020 , ... Coppe Healthcare Solutions (Coppe ... the laboratory division of the Open Medicine Institute based in San Francisco Bay ... Knox, the Virologist who previously co-founded what is now Viracor-Eurofins in the year ...
(Date:5/25/2020)... , ... May 25, 2020 , ... AltMed Florida ... continues its statewide expansion with a three-day, Memorial Day Opening, starting Monday May 25 ... Springs. , During the opening, staggered over three-days for crowd mitigation, all licensed Florida ...
Breaking Medicine Technology: